Open AccessVaricella-Zoster Virus and Subcutaneous Cytarabine: Correlation of In Vitro Sensitivities to Blood Levels
Author(s) -
Zaky Da,
Betts Rf,
Douglas Rg,
Kathleen Bengali,
Neil Gl
Publication year - 1975
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.7.3.229
Subject(s) - cytarabine , varicella zoster virus , virus , virology , medicine , aciclovir , in vitro , pharmacology , biology , viral disease , herpesviridae , chemotherapy , biochemistry
The susceptibility of 26 strains of varicella-zoster virus to cytarabine was tested in vitro by measuring reduction in number and size of plaques using human foreskin fibroblast cells. Most strains showed 50% reduction of plaque number by 0.125 μg of cytarabine per ml or less. Cytarabine levels in sera of 12 patients after a single subcutaneous injection of 50 mg/M2 exceeded this inhibitory level for a period of 75 min. Thus, the subcutaneous route is a potentially useful method of administration of cytarabine for antiviral drug trials.